FLT3 and acute myeloid leukemia: Importantly, similar to clonal heterogeneity in “bulk AML” potentially responsible for persistent MRD and treatment failure by clonal selection under conventional chemotherapy or following targeted therapy (e.g., breakthrough of FLT3-ITD-negative clones under midostaurin maintenance therapy) distinct LSC populations are hypothesized in AML patients.